Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SHE:301617)
China · Delayed Price · Currency is CNY 44.87
-0.06 (-0.13%)
At close: Nov 13, 2026
SHE:301617 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,795 | 10,393 | 5,265 | - | - | - | |
Market Cap Growth | -31.46% | 97.39% | - | - | - | - |
Enterprise Value | 7,186 | 9,632 | 4,955 | - | - | - |
Last Close Price | 44.87 | 59.53 | 29.69 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 45.24 | 60.32 | 24.74 | - | - | - |
Forward PE | - | 43.09 | - | - | - | - |
PS Ratio | 5.04 | 7.10 | 3.97 | - | - | - |
PB Ratio | 4.28 | 6.01 | 3.18 | - | - | - |
P/TBV Ratio | 4.43 | 6.23 | 3.30 | - | - | - |
P/FCF Ratio | 534.66 | - | 49.53 | - | - | - |
P/OCF Ratio | 67.61 | - | 32.55 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.65 | 6.58 | 3.73 | - | - | - |
EV/EBITDA Ratio | 31.61 | 42.07 | 18.30 | - | - | - |
EV/EBIT Ratio | 37.81 | 49.29 | 20.50 | - | - | - |
EV/FCF Ratio | 492.88 | - | 46.61 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0 | 0.00 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 |
Debt / FCF Ratio | 0.32 | - | 0.00 | 0.01 | 0.05 | 0.25 |
Net Debt / Equity Ratio | -0.33 | -0.38 | -0.58 | -0.28 | -0.23 | -0.15 |
Net Debt / EBITDA Ratio | -2.68 | -2.86 | -3.54 | -0.97 | -0.64 | -0.46 |
Net Debt / FCF Ratio | -41.78 | 7.43 | -9.01 | -2.88 | -2.72 | -5.80 |
Asset Turnover | 0.79 | 0.77 | 0.91 | 1.12 | 1.17 | 1.07 |
Inventory Turnover | 3.77 | 4.39 | 5.24 | 4.79 | 4.32 | 3.84 |
Quick Ratio | 3.92 | 4.35 | 5.03 | 1.88 | 1.48 | 1.66 |
Current Ratio | 6.34 | 6.71 | 6.07 | 2.78 | 2.29 | 2.89 |
Return on Equity (ROE) | 9.82% | 10.18% | 17.27% | 25.36% | 32.72% | 27.65% |
Return on Assets (ROA) | 6.08% | 6.41% | 10.40% | 14.28% | 18.91% | 15.96% |
Return on Invested Capital (ROIC) | 13.42% | 19.38% | 32.93% | 34.60% | 42.03% | 32.07% |
Return on Capital Employed (ROCE) | 10.40% | 11.30% | 14.60% | 25.90% | 33.00% | 27.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.21% | 1.66% | 4.04% | - | - | - |
FCF Yield | 0.19% | -0.85% | 2.02% | - | - | - |
Dividend Yield | 0.45% | 0.51% | 1.17% | - | - | - |
Payout Ratio | 25.62% | 51.32% | - | - | - | 1.90% |
Buyback Yield / Dilution | -11.74% | -73.20% | 23.12% | -0.08% | -4.17% | -0.84% |
Total Shareholder Return | -11.30% | -72.69% | 24.29% | -0.08% | -4.17% | -0.84% |